We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Chemotherapy Followed By PBSC Rescue for HD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186251
First Posted: September 16, 2005
Last Update Posted: November 12, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
September 13, 2005
September 16, 2005
November 12, 2012
March 1998
Not Provided
  • Overall survival
  • FFS
  • Response rates
  • - Overall survival
  • - FFS
  • - Response rates
Complete list of historical versions of study NCT00186251 on ClinicalTrials.gov Archive Site
Toxicity of high dose chemotherapy
Same as current
Not Provided
Not Provided
 
High Dose Chemotherapy Followed By PBSC Rescue for HD
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hodgkin Disease
Procedure: high dose chemo then auto hematopoietic cell transplant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
July 2005
Not Provided

Inclusion Criteria:- adequate organ function

  • recurrent HD Exclusion Criteria:- CNS disease
  • no prior malignancy
Sexes Eligible for Study: All
up to 70 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00186251
BMT24
BMT24
13322 ( Other Identifier: Stanford IRB )
Not Provided
Not Provided
Not Provided
Not Provided
Stanford University
Not Provided
Principal Investigator: Sally Arai Stanford University
Stanford University
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP